c-Met in chromophobe renal cell carcinoma
Erlmeier F, Ivanyi P, Hartmann A, Autenrieth M, Wiedemann M, Weichert W, Steffens S (2017)
Publication Type: Journal article
Publication year: 2017
Journal
Book Volume: 34
Pages Range: 15
Journal Issue: 2
DOI: 10.1007/s12032-016-0874-1
Abstract
c-Met plays a role as a prognostic marker in clear cell renal cell carcinoma. In addition, recently the tyrosine kinase inhibitor cabozantinib targeting c-Met was approved for the treatment of advanced renal cell carcinoma (RCC). In contrast to clear cell RCC, little is known about c-Met expression patterns in rarer RCC subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of c-Met expression on chromophobe (ch)RCC. Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for c-Met expression by immunohistochemistry. Expression data were associated with clinicopathological parameters including patient survival. Eighty-one chRCC patients were eligible for analysis. Twenty-four (29.6%) patients showed a high c-Met expression (c-Met(high), staining intensity higher than median). Our results showed an association between c-Met(high) expression and the existence of lymph node metastasis (p = 0.007). No further significant clinicopathological associations with c-Met were identified, also regarding c-Met expression and overall survival. In conclusion, to our knowledge this is the first study evaluating the prognostic impact of c-Met in a considerably large cohort of chRCC. High c-Met expression is associated with the occurrence of lymph node metastasis. This indicates that c-Met might be implicated into metastatic progression in chRCC.
Authors with CRIS profile
Involved external institutions
KfH-Nierenzentrum Jena
Germany (DE)
Technische Universität München (TUM)
Germany (DE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
Germany (DE)
Technische Universität München (TUM)
Germany (DE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
How to cite
APA:
Erlmeier, F., Ivanyi, P., Hartmann, A., Autenrieth, M., Wiedemann, M., Weichert, W., & Steffens, S. (2017). c-Met in chromophobe renal cell carcinoma. Medical Oncology, 34(2), 15. https://doi.org/10.1007/s12032-016-0874-1
MLA:
Erlmeier, Franziska, et al. "c-Met in chromophobe renal cell carcinoma." Medical Oncology 34.2 (2017): 15.
BibTeX: Download